<p>Actemra Infusion 400 mg contains Tocilizumab, an advanced biologic therapy used to treat autoimmune conditions like Rheumatoid Arthritis and severe COVID-19 complications. It works by blocking interleukin-6 (IL-6), reducing inflammation and immune system overactivity.</p>
Actemra Infusion 400 mg is a prescription biologic medication containing Tocilizumab, a monoclonal antibody specifically designed to treat inflammatory and autoimmune diseases. It is widely used in the management of Rheumatoid Arthritis and has also gained importance in treating severe cases of COVID-19, particularly those involving cytokine storm syndrome.
Manufactured by F. Hoffmann-La Roche, Actemra represents a modern advancement in targeted immunotherapy, offering relief for patients who do not respond to conventional treatments.
Tocilizumab is an interleukin-6 (IL-6) receptor antagonist. IL-6 is a cytokine involved in inflammation and immune responses.
In autoimmune diseases, IL-6 levels are elevated, leading to excessive inflammation. Actemra blocks this pathway, helping reduce inflammation and prevent joint and tissue damage.
Actemra is commonly used to treat moderate to severe Rheumatoid Arthritis in adults who have not responded to traditional therapies.
In severe COVID-19 cases, Actemra helps control the cytokine storm, a life-threatening immune overreaction.
Actemra works by inhibiting the IL-6 receptor, which plays a key role in inflammation.
This targeted action makes it highly effective compared to conventional anti-inflammatory drugs.
Actemra offers multiple benefits:
Actemra 400 mg is administered via intravenous infusion in a clinical setting.
Actemra is recommended for:
Immediate medical attention is required for severe symptoms.
Before using Actemra:
Actemra may interact with:
Always consult a healthcare provider before combining medications.
Actemra Infusion 400 mg is an imported biologic medicine and is usually available in:
Due to its high cost and specialized use, it is typically administered in clinical settings.
Actemra is preferred because:
Clinical studies show that Tocilizumab significantly improves symptoms in rheumatoid arthritis and reduces mortality in severe inflammatory conditions like cytokine storm in COVID-19.
Patients often experience:
Yes, when used under medical supervision.
No, but it helps control symptoms and disease progression.
Yes, infusion is usually administered in a hospital.
Yes, it is a high-cost biologic therapy.
No reviews yet. Be the first to review this product!